Inside Drug Pricing

MedPAC Member Suggests Expanding Insulin Cap Demo To Other Drugs

By John Wilkerson / January 18, 2022 at 2:35 PM

The Medicare demonstration that caps beneficiaries’ monthly insulin costs might be a model to consider for other highly rebated drugs that treat chronic conditions, if Congress fails to overhaul Part D, a congressional Medicare adviser said Friday (Jan. 14).

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

Inside Drug Pricing

MedPAC Member Suggests Expanding Insulin Cap Demo To Other Drugs

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.